# NEUROLOGÍA

www.elsevier.es/neurologia

ORIGINAL ARTICLE

New evidence of the relative protective effects of neurodegenerative diseases and cancer against each other[☆]

CrossMark

A. Robles Bayón[a],[*], F. Gude Sampedro[b]

[a] Unidad de neurología cognitiva, Hospital HM Rosaleda, Santiago de Compostela, Spain
[b] Unidad de epidemiología clínica, Hospital clínico universitario, Santiago de Compostela, Spain

Abstract

Background: Cancer and degenerative diseases share some pathogenic mechanisms which act in opposition to one another to produce either uncontrolled cell proliferation or cell death. According to several studies, patients with Alzheimer disease have a lower risk of neoplasia, and vice versa. This study describes the prevalence of tumours (active or successfully treated) in a series of patients with and without a dementing degenerative disease treated at a cognitive neurology unit.

Patients and method: We analysed the frequency and topography of tumours and the presence or absence of a neurodegenerative disease in a group of 1164 patients. Neurodegenerative diseases were classified in 4 groups: Alzheimer disease, synucleinopathies, Pick complex, and polyglutamine complex. We subsequently compared tumour frequency in patients with and without a degenerative disease, and prevalence of neurodegenerative diseases in patients with and without tumours.

Results: Tumours were detected in 12.1% of the patients with a neurodegenerative disease and in 17.3% of the remaining patients. Around 14.8% of the patients with a history of neoplasia and 20.8% of the patients with no history of neoplasia were diagnosed with a neurodegenerative disease. Except for these differences and the differences between subgroups (type of degenerative disease and tumour location) were not statistically significant, except when comparing neurodegenerative diseases to central nervous system tumours, and synucleinopathies to neoplasms.

Conclusion: Dementing degenerative diseases and neoplastic disorders are not mutually exclusive. Nevertheless, the rate of co-occurrence is lower than would be expected given the prevalence rate for each group.

---

[*] Corresponding author.
E-mail address: alfredorobles@hospitalrosaleda.com (A. Robles Bayón).

Nueva observación de la protección relativa que las enfermedades neurodegenerativas y el cáncer se confieren entre sí

Resumen

Introducción: El cáncer y las enfermedades degenerativas constituyen trastornos con algunos mecanismos compartidos que actúan en sentido opuesto, produciendo un fenómeno incontrolado de proliferación o pérdida de células. Observaciones diversas apuntan que los pacientes con enfermedad de Alzheimer tienen menor riesgo de desarrollar tumores y vice versa. En este artículo se expone la prevalencia de tumores (activos o superados) en pacientes de neurología cognitiva con y sin una enfermedad degenerativa demenciante.

Pacientes y método: En 1.164 pacientes se analizó la frecuencia y topografía de tumores y la presencia o ausencia de enfermedad neurodegenerativa, que se clasificó en 4 grupos (enfermedad de Alzheimer, sinucleinopatía, enfermedad del complejo Pick y del complejo de poliglutamina). Se comparó la frecuencia de tumor en los subgrupos con y sin enfermedad degenerativa, y de esta en los pacientes con y sin trastorno tumoral.

Resultados: Se registró proceso tumoral en el 12,1% de los pacientes con enfermedad neurodegenerativa y en el 17,3% del resto del grupo. En el grupo del estudio, un 14,8% de los que tienen antecedente tumoral fue diagnosticado de enfermedad neurodegenerativa, frente al 20,8% entre los que no tienen ese antecedente. Estas diferencias y las observadas en la comparación de subgrupos (tipo de enfermedad degenerativa y topografía del tumor) no alcanzaron significación estadística, excepto al contrastar enfermedades neurodegenerativas con tumores del sistema nervioso central y sinucleinopatías con neoplasias.

Conclusiones: Las enfermedades neoplásicas y las neurodegenerativas demenciantes no son excluyentes, aunque muestran menor asociación de la esperada por su respectiva prevalencia.

Introduction

In the same way as the 20th century saw a huge step forward in the field of infectious diseases, degenerative and neoplastic diseases constitute the great challenge of 21st century medicine. According to worldwide data from the World Health Organization's International Agency for Research on Cancer, there were 15 206 036 new cases of cancer (excluding non-melanoma skin cancer; 2 753 183 cases in the European Union and 227 076 in Spain) and 8 885 195 deaths due to cancer (1 341 938 in the European Union and 108 390 in Spain) in 2015.[1] The present study focuses on degenerative diseases that cause dementia. Despite focusing on a specific subgroup, incidence of these diseases is high. According to published epidemiological data, 7 million to 15 million new cases of degenerative diseases were recorded worldwide in 2015 (1.6 million in Europe and 100 000 in Spain).[2–5] Degenerative diseases constitute the third leading cause of moderate to severe disability in people older than 60 in developed countries, after sensory processing disorders and osteoarticular disorders.[6] The incidence of the most frequent neoplastic and neurodegenerative diseases increases with age[7,8]; the increase in life expectancy will therefore result in greater incidence, unless we develop treatments capable of reverting this trend.

Cancer is characterised by uncontrolled cell proliferation, while degenerative diseases are associated with spontaneous cell loss at a faster rate than that observed in normal ageing. This opposition suggests the possibility of common underlying biological mechanisms. Alterations in these regulatory mechanisms may promote either cell death or cell proliferation. Multiple pathophysiological circumstances are known to be involved in both degenerative diseases and cancer. Table 1 lists some of the factors associated with Alzheimer disease (AD),[9–36] although other degenerative diseases are associated with additional factors.[37]

Recent studies report reduced frequencies of tumours in patients with AD and lower rates of AD in patients with history of cancer[38–44]; this supports the hypothesis of shared aetiopathogenic mechanisms.[45–47] Although most studies focus on AD, some researchers describe the same phenomenon in patients with non-Alzheimer degenerative dementias.[48–50] This paves the way for research into treatments to prevent or modulate the progression of both degenerative diseases and cancer.

This study explores the prevalence of a wide range of neoplastic processes (either active or successfully treated) in a group of patients attending a cognitive neurology unit. Our patients had varying degrees of cognitive impairment with a wide range of causes (including neurodegenerative diseases); this allowed us to determine whether the presence of a neoplastic process (generic or specific) may modify the risk of developing neurodegenerative diseases, and vice versa.

Table 1 Proteins and genetic factors involved in the pathogenesis of Alzheimer disease and cancer, and bibliographical references of studies explaining their action mechanisms.

	Alzheimer disease	Cancer
ABC transporter	32	32
APP	9	10
Caveolin	11, 12	11
Clusterin	13	14
Epigenetic factors*	15, 16	17
γ-Secretase/presenilins	18	18
GSK-3	19, 20	20
p53	21	21, 22
PICALM	23	24
Pin1	25	25
Seladin-1	26	27, 28
Telomerase	29, 30	31
TREM-2	33	34
VDAC-1	19, 35	36

* DNA methylation, histone acetylation, non-coding RNA. ABC: ATP-binding cassette; APP: amyloid precursor protein; GSK-3: glycogen synthase kinase 3; PICALM: phosphatidylinositol binding clathrin assembly protein; Pin1: peptidyl-prolyl cis/trans isomerase 1; seladin-1: 24-dehydrocholesterol reductase; TREM-2: triggering receptor expressed on myeloid cells 2; VDAC-1: voltage-dependent anion channel 1.

Patients and methods

We analysed data from a register of patients attending a neurology clinic which primarily treats patients with cognitive impairment. At the initial consultation, we gathered data on age, sex, aetiological diagnosis, and history of tumours, whether active or successfully treated; this information is collected systematically. We excluded patients with uncertain aetiological diagnosis and those for whom information on history of tumours was imprecise or unreliable.

Patients were classified according to whether or not they had been diagnosed with a neurodegenerative disease with potential to cause dementia. For patients who did have neurodegenerative disease, we also recorded whether the diagnosis was AD, a disease of the Pick complex (frontotemporal dementia and its variants, corticobasal syndrome, and progressive supranuclear palsy), α-synucleinopathies (Parkinson's disease dementia, Lewy body dementia, multiple system atrophy),[51] or polyglutamine diseases (Huntington disease and some types of spinocerebellar atrophy).[52] All patients showed the typical cognitive, behavioural, and neuroimaging alterations (MRI, CT, and/or ^{18}F-fludeoxyglucose PET) of the symptomatic phase of each disease.

We established a topographical classification of tumours for those patients with cancer (Table 2). Central nervous system (CNS) tumours were grouped according to the 2016 classification of the World Health Organization.[53]

We performed a statistical analysis to detect any differences in the frequency of neoplastic diseases in general or any of the specific types recorded, between patients with and without a dementia-related neurodegenerative disease or any of its variants. The chi-square test and the Fisher exact test were used for this analysis; *P*-values <.05 were considered statistically significant. Odds ratios and 95% confidence intervals (CI) were used as the measure of association. Data were analysed using version 19.0 of the SPSS statistical software for Windows.

Results

Tables 2 and 3 summarise the clinical characteristics of our patient sample. Patients were mainly women, both in the total sample and in all subgroups. Our sample's mean age was above 70.

History of cancer (active or successfully treated) was recorded in 12.1% of patients with dementia-related neurodegenerative diseases and 17.3% of patients without. In our sample, 14.8% of patients with history of cancer and 20.8% of patients without had a diagnosis of neurodegenerative disease (Table 3); these differences were not statistically significant (*P* = .059).

We found significant differences in the frequency of CNS tumours between patients with and without neurodegenerative diseases as a whole (*P* = .028) (Table 4), and in the frequency of tumours between patients with and without α-synucleinopathies (*P* = .047) (Tables 5 and 6).

Discussion

We studied a sample of 1164 patients to analyse differences in the frequency of tumours in patients with and without dementia-related neurodegenerative diseases, and in the frequency of this type of diseases between patients with and without history of tumours.

The patients included were predominantly women (61.6%), which may be explained by the higher percentage of women in the study population (51.8%) and the higher incidence of dementia among women[2] (our sample was drawn from a cognitive neurology unit). However, the percentage of women differs significantly between the groups with and without history of tumours (54.5% vs 63%). This may be due to the higher incidence of cancer among men.[1,54]

Patients with neurodegenerative diseases were older than those without (*P* < .034); the same was true for patients with history of cancer compared to those without (*P* < .001). This was to be expected given the age-dependent increase in the incidences of AD and Lewy body dementia (which account for more than half of cases of dementia) and cancer.[8,55]

Our results show a lower frequency of tumours among patients with dementia-related neurodegenerative diseases, and vice versa (Table 3). These data show a trend towards significance (*P* = .059). In the subgroup analysis, however, differences show a much less clear trend towards significance due to the smaller size of each subgroup. CNS tumours were significantly less frequent among patients with neurodegenerative diseases (one in 231 patients) than among those without (26 in 933 patients) (Table 4).

Our results are consistent with findings reported in the literature. Most studies report a lower incidence of tumours in patients with dementia-related neurodegenerative

Table 2 Distribution of the patient sample by type of neurodegenerative disease and cancer.

Cancer	Neurodegenerative disease					
	No	Yes	AD	α-Syn	Pick	Polygl
No	772	203	74	46	82	1
Yes	161	28	13	3	12	0
Skin	15	7	3	0	4	0
Non-melanoma	10	6	3	0	3	0
Melanoma	5	1	0	0	1	0
Salivary glands	2	0	0	0	0	0
Tongue	1	0	0	0	0	0
Thyroid	1	0	0	0	0	0
Laryngeal	2	0	0	0	0	0
Lung	6	0	0	0	0	0
Digestive system	24	3	2	0	1	0
Stomach	4	0	0	0	0	0
Gallbladder	1	0	0	0	0	0
Colorectal	19	3	2	0	1	0
Bladder	6	1	0	0	1	0
Prostate	23	5	3	1	1	0
Kidney	7	1	0	0	1	0
Adrenal gland	2	0	0	0	0	0
Ovarian	5	1	0	0	1	0
Uterine	18	6	4	1	1	0
Breast	30	4	1	0	3	0
Bone	4	0	0	0	0	0
Haematopoietic bone marrow	4	0	0	0	0	0
Central nervous system	26	1	0	1	0	0
Meninges	13	0	0	0	0	0
Brain	8	1	0	1	0	0
Vestibulocochlear nerve	5	0	0	0	0	0
Carotid body and glomus jugulare	1	0	0	0	0	0
Lymph nodes	3	0	0	0	0	0

α-Syn: α-synucleinopathies; AD: Alzheimer disease; Pick: diseases of the Pick complex; polygl: polyglutamine diseases.

Table 3 Characteristics of patients included in the study.

	Degenerative disease	No degenerative disease	Total
Cancer	28	161	189
	(12.1; 14.8; 60.7; 76.8)	(17.3; 85.2; 53.4; 77.7)	(16.2; 100; 54.5; 77.6)
No cancer	203	772	975
	(87.9; 20.8; 59.6; 74.6)	(82.7; 79.2; 63.9; 72.3)	(83.8; 100; 63.0; 72.8)
Total	231	933	1164
	(100; 19.8; 59.7; 74.9)	(100; 80.2; 62.1; 73.3)	(100; 100; 61.6; 73.6)

Data are presented as number of cases (% of column; % of row; % women; mean age).

Table 4 Presence of central nervous system tumours in patients with and without dementia-related neurodegenerative diseases.

	Degenerative disease	No degenerative disease	Total
CNS tumour	1	26	27
	(0.4; 3.7)	(2.8; 96.3)	(2.3; 100)
No CNS tumour	230	907	1137
	(99.6; 20.2)	(97.2; 79.8)	(97.7; 100)
Total	231	933	1164
	(100; 19.8)	(100; 80.2)	(100; 100)

CNS: central nervous system.
Data are presented as number of cases (% of column; % of row).

Table 5 Presence of tumours in patients with different types of neurodegenerative disease.

	% tumour in A/B	OR	95% CI	P
Degenerative disease	12.1/17.3	0.66	0.43-1.01	.059
Alzheimer disease	14.9/17.3	0.84	0.45-1.55	.65
α-Synucleinopathies	6.1/17.3	0.31	0.09-1.01	**.047**
Pick complex	12.8/17.3	0.70	0.37-1.31	.31

95% CI: 95% confidence interval; A: patients with the disease indicated in the row; B: patients without degenerative diseases; OR: odds ratio.
The only statistically significant result is shown in bold (P < .05).

Table 6 Presence of tumours in patients diagnosed with α-synucleinopathies or no degenerative disease.

	α-Synucleinopathies	No degenerative disease	Total
Tumour	3	161	164
	(6.1; 1.8)	(17.3; 98.2)	(16.7; 100)
No tumour	46	772	818
	(93.9; 5.6)	(82.7; 94.4)	(83.3; 100)
Total	49	933	982
	(100; 5.0)	(100; 95.0)	(100; 100)

Data are presented as number of cases (% of column; % of row).

diseases and a lower incidence of the latter in patients with a history of cancer. Our results, however, show that these diseases are not mutually exclusive; some observations even reveal an association between them. Although results are heterogeneous (between studies and types of tumour), a meta-analysis of multiple studies shows a significantly weaker association between neurodegenerative diseases and cancer.[38–40]

With respect to type of neurodegenerative diseases, both our results and those of other studies show a negative association between cancer and AD.[48–50] Our study also found a lower prevalence of tumours among patients with α-synucleinopathies. In addition to its role in the development of dementia-related α-synucleinopathies, α-synuclein is expressed in several types of tumour, including brain tumours with a neuronal component,[56] schwannomas,[57] melanomas and benign nevi,[58] ovarian tumours,[59] and myelodysplastic syndromes.[60] This is not always reflected by epidemiological data, however. Some series of patients with Parkinson's disease show a higher incidence of melanoma,[50,61] while others report the opposite.[50,62] Some studies have found a higher incidence of brain tumours[50,63] and breast cancer[50,61] and a lower risk of lung and colorectal cancer in patients with Parkinson's disease.[64] Tumours are generally less frequent in patients with Parkinson's disease[62] or Lewy body dementia.[48] In any case, the inconsistent results suggest that mutual protection is neither strong nor uniform, probably due to the involvement of other factors.

Analysis by tumour type shows less marked, more heterogeneous differences: Ou et al.[42] found a significantly lower incidence of lung cancer in men with AD; Realmuto et al.[65] found AD to be associated with significant differences in cancer risk in women and for endocrine tumours; and Roe et al.[44] and Behrens et al.[66] found differences for skin tumours. Our study found significant differences only when assessing CNS tumours as a single category. Classifying patients by tumour location results in small sample sizes, which prevents detection of statistically significant differences unless effect sizes are large. According to our results, only 2 types of tumour (non-melanoma skin cancer and uterine cancer) were more frequent among patients with degenerative diseases (2.6% for both types of cancer) than in the remaining participants (1.1% and 1.9%, respectively); the differences were not significant, however (Table 2). The analysis by tumour type resulted in small subgroups. The lack of significant differences prevents us from concluding that the presence of any of these tumours protects against neurodegenerative diseases.

The differences observed for CNS tumours merit some consideration. Hypothetically, the potential interference between the mechanisms of cell proliferation and cell death would seem to be more likely to occur in diseases affecting the same organ or system (e.g., the brain, the CNS). Therefore, development of a degenerative disease of the brain would be more compatible with a proliferative process affecting the lung or any other organ not associated with the nervous system. It should be noted that the genetic alterations known to cause cancer and degenerative diseases (causal mutations and risk genotypes) do not overlap. A review article by Richterová et al.[67] lists over 60 genes involved in the pathogenesis of brain tumours, none of which coincide with any of the 30 genes currently known to be associated with AD.[68] A single person may present genetic and environmental factors associated with degenerative diseases and cancer, and may therefore develop both. Neither our findings nor those of previous studies suggest that either type of disease precludes the other; rather, they show that the association between degenerative diseases and cancer is less frequent than the occurrence of these entities separately. This relative protection may be due to shared pathogenic mechanisms acting in opposite directions (Table 1).

Subgroup analysis by type of tumour or degenerative disease finds less clear differences due to the smaller sample size. The small number of patients with polyglutamine diseases and the low frequency of some types of tumour may be responsible for their low prevalence at advanced ages. In any case, the small number of cases prevents us from determining whether there is a relationship of intense cross-protection between the 2 entities. Some highly frequent types of cancer, including lung, stomach, liver, and oesophageal cancer, may be underrepresented due to the high associated mortality rates.[1] This means that a large percentage of patients with these tumours would die before reaching the risk age for developing dementia-related neurodegenerative diseases. We may hypothesise that if it were not for this increase in the mortality rate, the association observed in our study would be even less marked. To minimise this bias, all patients with tumours and long survival times should be followed up.

The same is true of patients with degenerative diseases, which are associated with increased mortality rates (1.4 to 2.7 times higher).[69,70] This means that the incidence of tumours associated with advanced age (which would develop later in life) will be lower in these patients than in individuals of the same age but without degenerative diseases.

According to the literature and to our own results, neurodegenerative diseases and cancer are not mutually exclusive, although the rate of co-occurrence is lower than expected considering the prevalence of each type of disease separately. This phenomenon is therefore of little use in clinical practice, since the presence of one of these diseases does not rule out the other when the patient shows compatible signs or symptoms. However, the low incidence of the combination of both types of disease points to the involvement of biases associated with the high mortality rates of both types of diseases, as well as common pathogenic mechanisms acting in opposite directions. Our findings underscore the importance of exploring treatments targeting these mechanisms, as these studies have greater translational value, and may result in the development of drugs capable of treating the 2 types of diseases with the highest mortality and disability rates worldwide.

Funding

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. International Agency for Research on Cancer. World Health Organization. Global cancer observatory. Available from: http://gco.iarc.fr [accessed 10.12.16].
2. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M, Alzheimer's Disease International. World Alzheimer Report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost and trends. Londres: Alzheimer's Disease International; 2015.
3. Jetté N, Maxwell CJ, Fiest KM, Hogan DB. Systematic reviews and meta-analyses of the incidence and prevalence of dementia and its commoner neurodegenerative causes. Can J Neurol Sci. 2016;43:S1—2.
4. Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis. Neurología. 2017;32:523—2.
5. Garre-Olmo J, Genís Batlle D, Fernández MM, Marquez Daniel F, Huélano RE, Casadevall T, et al. Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology. 2010;75:1249—55.
6. Organización Mundial de la Salud, Banco Mundial. Informe mundial sobre la discapacidad. Organización Mundial de la Salud; 2011.
7. Feitelson DG. Data on the distribution of cancer incidence and death across age and sex groups visualized using multilevel spie charts. J Clin Epidemiol. 2016;72:90—7.
8. De Pedro-Cuesta J, Rábano A, Martínez-Martín P, Ruiz-Tovar M, Alcalde-Cabero E, Almazán-Isla J, et al. Comparative incidence of conformational, neurodegenerative disorders. PLOS ONE. 2015;10:e0137342.
9. Zhang H, Ma Q, Zhang Y, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem. 2012;120 Suppl 1:9—21.
10. Pandey P, Sliker B, Peters HL, Tuli A, Herskovitz J, Smits K, et al. Amyloid precursor protein and amyloid precursor-like protein 2 in cancer. Oncotarget. 2016;7:19430—44.
11. Engelman JA, Zhang X, Galbiati F, Volonté D, Sotgia F, Pestell RG, et al. Molecular genetics of the caveolin gene family: Implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Am J Hum Genet. 1998;63:1578—87.
12. Kapoor A, Hsu WM, Wang BJ, Wu GH, Lin TY, Lee SJ, et al. Caveolin-1 regulates γ-secretase-mediated AβPP processing by modulating spatial distribution of γ-secretase in membrane. J Alzheimers Dis. 2010;22:423—42.
13. Tan L, Wang HF, Tan MS, Tan CC, Zhu XC, Miao D, et al. Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. Sci Rep. 2016;6:26027.
14. Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A. Regulation of CLU gene expression by oncogenes and epigenetic factors: Implications for tumorigenesis. Adv Cancer Res. 2009;105:115—32.
15. Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HWM, Mastroeni D, et al. The epigenetics of aging and neurodegeneration. Prog Neurobiol. 2015;131:21—64.
16. Yu L, Chibnik LB, Srivastava GP, Pochet N, Yang J, Xu J, et al. Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol. 2015;72:15—24.
17. Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform. 2013;11:164—73.
18. Strooper BD, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006304.
19. Reddy PH. Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta. 2013;1832:1913—21.
20. Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114—31.
21. Nakanishi A, Minami A, Kitagishi Y, Ogura Y, Matsuda S. BRCA1 and p53 tumor suppressor molecules in Alzheimer's disease. Int J Mol Sci. 2015;16:2879—92.

22. Haupt S, Raghu D, Haupt Y. Mutant p53 drives cancer by sub-verting multiple tumor suppression pathways. Front Oncol. 2016;6:12.

23. Xu W, Tan L, Yu JT. The role of PICALM in Alzheimer's disease. Mol Neurobiol. 2015;52:399—413.

24. Scotland PB, Heath JL, Conway AE, Porter NB, Armstrong MB, Walker JA, et al. The PICALM protein plays a key role in iron homeostasis and cell proliferation. PLoS ONE. 2012;7:e44252.

25. Lee TH, Pastorino L, Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med. 2011;13:e21.

26. Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, et al. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience. 2002;113:301—10.

27. Simi L, Malentacchi F, Luciani P, Gelmini S, Deledda C, Arvia R, et al. Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC Cancer. 2010;10:201.

28. Battista MC, Guimond MO, Roberge C, Doueik AA, Fazli L, Gleave M, et al. Inhibition of DHCR24/Seladin-I impairs cellular homeo-stasis in prostate cancer. Prostate. 2010;70:921—33.

29. Cai Z, Yan L-J, Ratka A. Telomere shortening and Alzheimer's disease. Neuromolecular Med. 2013;15:25—48.

30. Zhan Y, Song C, Karlsson R, Tillander A, Reynolds CA, Pedersen NL, et al. Telomere length shortening and Alzheimer disease — a mendelian randomization study. JAMA Neurol. 2015;72:1202—3.

31. Shay JW, Wright WE. Role of telomeres and telomerase in can-cer. Semin Cancer Biol. 2011;21:349—53.

32. Hartz AMS, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv. 2010;10:293—304.

33. Cheng J, Guo X, Zhang T, Zhong L, Bu G, Chen X. TREMs in Alzheimer's disease: genetic and clinical investigations. Clin Chim Acta. 2016;463:88—95.

34. Wang XQ, Tao BB, Li B, Wang XH, Zhang WC, Wan L, et al. Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma. Oncotarget. 2016;7:2354—66.

35. Smilansky A, Dangoor L, Nakdimon I, Ben-Hail D, Mizrachi D, Shoshan-Barmatz V. The voltage-dependent anion channel 1 mediates amyloid β toxicity and represents a poten-tial target for Alzheimer disease therapy. J Biol Chem. 2015;290:30670—83.

36. Shoshan-Barmatz V, Golan M. Mitochondrial VDAC1: function in cell life and death and a target for cancer therapy. Curr Med Chem. 2012;19:714—35.

37. Plun-Favreau H, Lewis PA, Hardy J, Martins M, Wood NW. Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet. 2010;6:e1001257.

38. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neu-rosurg Psychiatry. 2015;86:1299—306.

39. Catalá-López F, Crespo-Facorro B, Vieta E, Valderas JM, Valencia A, Tabarés-Seisdedos R. Alzheimer's disease and cancer: current epidemiological evidence for a mutual protection. Neuroepi-demiology. 2014;42:121—2.

40. Shi HB, Tang B, Liu YW, Wang XF, Chen GJ. Alzheimer dis-ease and cancer risk: a meta-analysis. J Cancer Res Clin Oncol. 2015;141:485—94.

41. Musicco M, Adorni F, di Santo S, Prinelli F, Pettenati C, Caltagirone C, et al. Inverse occurrence of cancer and Alzheimer disease. A population-based incidence study. Neu-rology. 2013;81:322—8.

42. Ou SM, Lee YJ, Hu YW, Liu CJ, Chen TJ, Fuh JL, et al. Does Alzheimer's disease protect against cancers? A nationwide population-based study. Neuroepidemiology. 2013;40:42—9.

43. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.

44. Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74:106—12.

45. Migliore L, Coppedè F. Genetic and environmental fac-tors in cancer and neurodegenerative diseases. Mutat Res. 2002;512:135—53.

46. De Moura MB, dos Santos LS, van Houten B. Mitochondrial dys-function in neurodegenerative diseases and cancer. Environ Mol Mutagen. 2010;51:391—405.

47. Staropoli JF. Tumorigenesis and neurodegeneration: two sides of the same coin. BioEssays. 2008;30:719—27.

48. Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, et al. Risk factors for dementia with Lewy bodies. Neurology. 2013;81:833—40.

49. Sørensen SA, Fenger K, Olsen JH. Significantly lower inci-dence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract. Cancer. 1999;86:1342—6.

50. Feng DD, Cai W, Chen X. The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener. 2015;4:20.

51. Peelaerts W, Baekelandt V. α-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem. 2016;139 Suppl 1:256—74.

52. Robles A. Los complejos de las demencias degenerativas: una evolución de la enfermedad al espectro. Neurología. 2009;24:399—418.

53. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous sys-tem: a summary. Acta Neuropathol. 2016;131:803—20.

54. Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España 2016. Acceso libre en internet. Available from: http://www.seom.org/seomcms/images/stories/recursos/LAS_CIFRAS_DEL_CANCER_EN_ESP_2016.pdf.

55. Frank SA. Age of cancer incidence. In: Frank SA, editor. Dynamics of cancer: incidence, inheritance, and evolution. Princeton — New Jersey (EE. UU.) y Woodstock — Oxford-shire (Inglaterra): Princeton University Press; 2007. p. 17—35. Cap. 2. Acceso libre en internet. Available from: https://stevefrank.org/cancer/cancerbook.pdf

56. Kawashima M, Suzuki SO, Doh-ura K, Iwaki T. Alpha-synuclein is expressed in a variety of brain tumors showing neuronal differ-entiation. Acta Neuropathol. 2000;99:154—60.

57. Mori F, Inenaga C, Yoshimoto M, Umezu H, Tanaka R, Takahashi H, et al. Alpha-synuclein immunoreactivity in normal and neo-plastic Schwann cells. Acta Neuropathol. 2002;103:145—51.

58. Matsuo Y, Kamitani T. Parkinson's disease-related pro-tein, alpha-synuclein, in malignant melanoma. PLoS ONE. 2010;5:e10481.

59. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 2000;88:2154—63.

60. Maitta RW, Wolgast LR, Wang Q, Zhang H, Bhattacharyya P, Gong JZ, et al. Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia. Am J Hematol. 2011;86:230—4.

61. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers. Neurology. 2007;69:1542—50.

62. Tacik P, Curry S, Fujioka S, Strongosky A, Uitti RJ, van Gerpen JA, et al. Cancer in Parkinson's disease. Parkinsonism Relat Disord. 2016;31:28—33.

63. Ye R, Shen T, Jiang Y, Xu L, Si X, Zhang B. The relationship between Parkinson disease and brain tumor: a meta-analysis. PLOS ONE. 2016;11:e0164388.

64. Peretz C, Gurel R, Rozani V, Gurevich T, El-Ad B, Tsamir J, et al. Cancer incidence among Parkinson's disease in a 10-yrs time-window around disease onset: a large-scale cohort study. Parkinsonism Relat Disord. 2016;28:68—72.

65. Realmuto S, Cinturino A, Arnao V, Mazzola MA, Cupidi C, Aridon P, et al. Tumor diagnosis preceding Alzheimer's disease onset: is there a link between cancer and Alzheimer's disease. J Alzheimers Dis. 2012;31:177—82.

66. Behrens MI, Roe CM, Morris JC. Inverse association between cancer and dementia of the Alzheimer's type. In: von Bernhardi R, Inestrosa NC, editors. Neurodegenerative diseases: from molecular concepts to therapeutic targets. New York: Nova Science Publishers; 2008. p. 111—20 [Chapter 9].

67. Richterová R, Jurečeková J, Evinová A, Kolarovszki B, Benčo M, De Riggo J, et al. Most frequent molecular and immunohistochemical markers present in selected types of brain tumors. Gen Physiol Biophys. 2014;33:259—79.

68. Van Cauwenberghe C, van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18:421—30.

69. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality — a 15-year epidemiological study. Arch Neurol. 2005;62:779—84.

70. Garcia-Ptacek S, Farahmand B, Kåreholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish dementia registry. J Alzheimers Dis. 2014;41:467—77.